# reload+after+2024-01-21 15:27:28.091269
address1§430 East 29th Street
address2§14th Floor
city§New York
state§NY
zip§10016
country§United States
phone§212 546 4000
website§https://www.bms.com
industry§Drug Manufacturers—General
sector§Healthcare
longBusinessSummary§Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
fullTimeEmployees§34300
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Giovanni  Caforio M.D.', 'age': 58, 'title': 'Executive Chairman of the Board', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 5763527, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher S. Boerner Ph.D.', 'age': 52, 'title': 'CEO & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 2624023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David V. Elkins', 'age': 55, 'title': 'Executive VP & CFO', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 2724676, 'exercisedValue': 2826282, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sandra  Leung Esq.', 'age': 62, 'title': 'Executive VP & General Counsel', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 2663774, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Greg  Meyers', 'age': 50, 'title': 'Executive VP and Chief Digital & Technology Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Timothy  Power', 'title': 'VP & Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kimberly M. Jablonski', 'title': 'Chief Compliance & Ethics Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ann M. Powell Judge', 'age': 57, 'title': 'Executive VP & Chief Human Resources Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Samit  Hirawat M.D.', 'age': 54, 'title': 'Executive VP & Chief Medical Officer of Drug Development', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joseph J. Eiden Jr.', 'age': 74, 'title': 'Head of Medical Affairs', 'yearBorn': 1949, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§6
compensationRisk§1
shareHolderRightsRisk§2
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
dividendRate§2.4
dividendYield§0.046
exDividendDate§1704326400
payoutRatio§0.5787
fiveYearAvgDividendYield§3.16
beta§0.342
priceToSalesTrailing12Months§2.3650942
currency§USD
dateShortInterest§1702598400
forwardEps§7.24
pegRatio§-19.69
exchange§NYQ
quoteType§EQUITY
shortName§Bristol-Myers Squibb Company
longName§Bristol-Myers Squibb Company
firstTradeDateEpochUtc§76253400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§124a4488-9ef3-3d5f-ba4c-95716202653d
gmtOffSetMilliseconds§-18000000
targetHighPrice§85.0
targetLowPrice§42.0
targetMeanPrice§60.38
targetMedianPrice§60.0
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§21
quickRatio§0.994
earningsGrowth§0.24
grossMargins§0.77009004
ebitdaMargins§0.40654
trailingPegRatio§0.5889
